BEXIMCO PHARMA.GDR REGS 1 (R2WA) - Total Liabilities
Based on the latest financial reports, BEXIMCO PHARMA.GDR REGS 1 (R2WA) has total liabilities worth €20.17 Billion EUR (≈ $23.58 Billion USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore R2WA net asset momentum to track the company's year-over-year net asset growth rate.
BEXIMCO PHARMA.GDR REGS 1 - Total Liabilities Trend (2021–2024)
This chart illustrates how BEXIMCO PHARMA.GDR REGS 1's total liabilities have evolved over time, based on quarterly financial data. See R2WA free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
BEXIMCO PHARMA.GDR REGS 1 Competitors by Total Liabilities
The table below lists competitors of BEXIMCO PHARMA.GDR REGS 1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Investcorp Europe Acquisition I Corp
NASDAQ:IVCB
|
USA | $10.09 Million |
|
Minerva Neurosciences Inc
NASDAQ:NERV
|
USA | $348.04 Million |
|
Transgene SA
PA:TNG
|
France | €17.09 Million |
|
KYE Systems Corp
TW:2365
|
Taiwan | NT$446.99 Million |
|
Holiday Entertainment Co Ltd
TW:9943
|
Taiwan | NT$2.09 Billion |
|
Sakar Healthcare Limited
NSE:SAKAR
|
India | Rs1.57 Billion |
|
Sunjuice Holdings Co Ltd
TW:1256
|
Taiwan | NT$1.17 Billion |
|
DFI Inc
TW:2397
|
Taiwan | NT$6.65 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down BEXIMCO PHARMA.GDR REGS 1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of BEXIMCO PHARMA.GDR REGS 1.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.41 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BEXIMCO PHARMA.GDR REGS 1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BEXIMCO PHARMA.GDR REGS 1 (2021–2024)
The table below shows the annual total liabilities of BEXIMCO PHARMA.GDR REGS 1 from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-06-30 | €17.44 Billion ≈ $20.39 Billion |
-19.02% |
| 2023-06-30 | €21.54 Billion ≈ $25.18 Billion |
+0.12% |
| 2022-06-30 | €21.51 Billion ≈ $25.15 Billion |
+44.56% |
| 2021-06-30 | €14.88 Billion ≈ $17.40 Billion |
-- |
About BEXIMCO PHARMA.GDR REGS 1
Beximco Pharmaceuticals PLC. manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskelet… Read more